Oncocyte Q2 revenue $0.5M, net operating loss $8.3M; appoints James Liu interim CFO

Insight Molecular Diagnostics Inc.

2023-Q2 EPS reported -$0.83 revenue$760,000

Revenue $0.5M, cost of revenue $0.2M; net operating loss $8.3M vs $8.6M YoY, down $0.3M.
Cash, equivalents, and marketable securities $17.9M at June 30; avg cash burn below $5M/qtr in 2H 2023.
R&D expense down 56% YoY to $2.4M; G&A down 36% to $3.5M; S&M down 77% to $0.8M.
Transplant product launch on track for Q4 early access; MolDX coverage reviews ongoing.
James Liu (age 28) promoted to Sr. Director, Controller & PAO; appointed interim Principal Financial Officer; salary $200K, target bonus 35%.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

James Liu

interim Principal Financial Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2023-08-04
Filed: August 10, 2023, 7:59 PM ET

On that same date, the Company appointed Mr. Liu to the additional role of interim Principal Financial Officer.

Role change

James Liu

Senior Director, Controller & Principal Accounting Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2023-08-04
Filed: August 10, 2023, 7:59 PM ET

On August 4, 2023, the Company promoted James Liu to Senior Director, Controller & Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Insight Molecular Diagnostics Inc. reported Second Quarter 2023 results: revenue 0.5 million.

Period: Second Quarter 2023
Revenue: 0.5 million
Result: reported results

Exact text from the filing

Consolidated revenues for the second quarter of 2023 were approximately $0.5 million, and cost of revenues for the second quarter were approximately $0.2 million, primarily from services customers.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Liu was appointed as interim Principal Financial Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: interim Principal Financial Officer

Exact text from the filing

On that same date, the Company appointed Mr. Liu to the additional role of interim Principal Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Liu changed role as Senior Director, Controller & Principal Accounting Officer at Insight Molecular Diagnostics Inc..

Action: promoted
Role: Senior Director, Controller & Principal Accounting Officer

Exact text from the filing

On August 4, 2023, the Company promoted James Liu to Senior Director, Controller & Principal Accounting Officer.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027440

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.